A patient with giant-cell glioblastoma benefited from procarbazine for a long period of time, then received combined therapy with bevacizumab and nivolumab, followed by targeted therapy with everolimus, due to the presence of NF1 mutation. Here, NF1 is linked to giant cell glioblastoma.